Karyopharm Therapeutics (KPTI) Depreciation & Amortization (CF) (2012 - 2025)

Karyopharm Therapeutics (KPTI) has 14 years of Depreciation & Amortization (CF) data on file, last reported at $19000.0 in Q4 2025.

• Quarterly Depreciation & Amortization (CF) fell 76.54% year-over-year to $19000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $296000.0 (down 12.94% YoY) and the FY2025 annual result came in at $296000.0, down 12.94% from the prior year.
• Depreciation & Amortization (CF) declined to $19000.0 in Q4 2025, from $121000.0 in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $290000.0 in Q1 2023 to a low of $19000.0 in Q4 2025.
• A 5-year average of $128800.0 and a median of $102000.0 in 2022 frame the typical range for Depreciation & Amortization (CF).
• Annual changes were most pronounced in 2023 — Depreciation & Amortization (CF) surged 63.84% — and 2025, when it plunged 76.54%.
• Tracing KPTI's Depreciation & Amortization (CF) over 5 years: stood at $139000.0 in 2021, then retreated by 18.71% to $113000.0 in 2022, then tumbled by 31.86% to $77000.0 in 2023, then rose by 5.19% to $81000.0 in 2024, then tumbled by 76.54% to $19000.0 in 2025.
• The last three Depreciation & Amortization (CF) figures came in at $19000.0 (Q4 2025), $121000.0 (Q3 2025), and $78000.0 (Q2 2025), per Business Quant data.